Join us for the 19th Annual Scientific Conference hosted by the Academy for Sickle Cell and Thalassaemia (ASCAT), in collaboration with the prestigious British Society of Haematology and the European Hematology Association, supported by Eurobloodnet (EBN) and various patient groups. Discover the latest breakthroughs in haemoglobinopathies at this groundbreaking event. Whether you're a healthcare professional, researcher, or someone affected by these conditions, the ASCAT Conference offers a unique opportunity to stay informed.
Explore new advancements in diagnosis, treatment, and emerging therapies for Sickle Cell Disease and Thalassemia. Engage in insightful discussions, witness cutting-edge research presentations, and network with peers to contribute to the continuous evolution of this field.
Selected abstracts will be featured in HemaSphere (EHA) journals, ensuring widespread dissemination of vital discoveries. Additionally, earn CPD and CME credits to enhance your professional growth. Join us at ASCAT and be part of the progress in haemoglobinopathies.
In alignment with our conference's overarching goal, centered on "Improving the lives of those living with Sickle Cell Disease & Thalassaemia," our discussions emphasize the critical need for collective action to address these conditions. Despite advancements in therapies, including gene therapies, it is essential to acknowledge persistent systemic inequities in accessing these innovations, particularly within marginalized communities.
As we gather to explore innovative approaches, our priority is to foster collaboration among patient groups, medical professionals, researchers, policymakers, and affected communities to address these challenges. Through this congress, we aim to raise awareness, enhance care accessibility, and drive transformative research initiatives, all with the ultimate goal of ensuring equitable support and an improved quality of life for all individuals impacted by these haemoglobinopathies.
Join us in making a meaningful impact on the lives of those affected by Sickle Cell Disease and Thalassaemia. Partner with us to support our objectives and contribute to the advancement of equitable care and ground-breaking research initiatives. Together, we can create lasting change and improve outcomes for individuals living with haemoglobinopathies.
This year’s program features five key elements:
- Sickle Cell Disease: Delve into the latest advancements in diagnosis, treatment, and care for individuals affected by Sickle Cell Disease.
- Thalassaemia: Gain comprehensive insights into disease management strategies and emerging therapies for Thalassaemia patients.
- Basic Research: Explore groundbreaking discoveries and experimental approaches driving innovation in the understanding and treatment of hemoglobinopathies.
- Patient/Caregiver/Advocacy: Hear firsthand from patients, caregivers, and advocates, care and advocacy efforts within the community.
- Meet the Expert: Engage in informal sessions with leading professionals, fostering knowledge exchange, collaboration, and the exploration of new ideas and approaches.
In addition to our core program, ASCAT 2024 proudly hosts sponsored symposiums, providing industry partners with a platform to showcase their latest innovations. Explore exhibitions to discover cutting-edge technologies and resources shaping the future of care in the field.
